Biotech Co. Says Red Cross Plainly Violated Antitrust Law

By Matthew Perlman · May 23, 2023, 5:30 PM EDT

A biotech company defended its suit in Massachusetts federal court accusing the American National Red Cross of snuffing out competition in the platelet bacteria mitigation market, contending the case is straightforward...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Response

Case Information

Case Title

Verax Biomedical Inc. v. American National Red Cross

Case Number

Court

Massachusetts

Nature of Suit

Anti-Trust

Date Filed

February 14, 2023

Recent Articles By Matthew

July 19, 2024
Boehringer Looks To Toss Inhaler Antitrust Case
July 17, 2024
Boehringer Wants Inhaler Antitrust Case Moved To Mass.
July 10, 2024
Buyers Say Teva Had Multipart Scheme To Delay Inhaler Rivals
July 09, 2024
FTC Says Drug Middlemen Inflate Costs, Squeeze Pharmacies
June 24, 2024
Justices Won't Hear Objections To $2.67B BCBS Deal
June 10, 2024
Health Data Co. Says Rival's Request Risks Patient Security
June 04, 2024
Nurse Staffing Exec Wants Antitrust, Fraud Charges Separated
May 28, 2024
HIV Drug Buyers Fight Bid To Combine 9th Circ. Appeal Briefs
May 24, 2024
Software-Aided Price Fixing Under Antitrust Assault
May 16, 2024
Gilead, Teva Want 17 HIV Drug Antitrust Appeals Consolidated